000518.SZ
四环生物
SZSE · Healthcare · C 制造业 · CN
CNY 3.70
−2.63%Year over year
Reported trailing growth
- Revenue
- +99.9%
- EBITDA
- —
- EBIT
- +56.9%
- EPS
- +73.6%
- Free cash flow
- +3547.5%
- Operating cash flow
- +810.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- +55.4%
- EBIT
- +48.6%
- Net income
- +66.3%
- EPS
- +66.3%
- Free cash flow
- +1917.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026